Is GHK-Cu FDA-approved for hair loss?

No. The FDA has not approved GHK-Cu for hair loss or any form of alopecia. The compounded 1% scalp solution and the GHK-Cu creams and serums are prepared under section 503A to an individual prescription and have not been evaluated by the FDA. Injectable GHK-Cu carries a separate FDA entry: placed in category 2 of the 503A bulk substances policy, with the nomination withdrawn in April 2026.

What did the follicle organ-culture study on copper peptides actually use?

The 2007 study by Pyo and colleagues in Archives of Pharmacal Research used AHK-Cu, alanyl-histidyl-lysine complexed with copper, a structural relative of GHK-Cu. It reported follicle elongation and dermal papilla cell proliferation in organ culture. The finding is relevant to copper peptides as a class and is not a finding about GHK-Cu itself.

Has GHK-Cu been tested in a human hair loss trial?

No randomised controlled trial of GHK-Cu in human pattern hair loss has been published as of this review. The hair-specific evidence is organ culture with a related peptide and a 1993 primate model of copper-binding peptides. The human GHK-Cu literature is concentrated in skin, cosmetic formulations and wound studies.

What does the FDA entry for GHK-Cu say, and does it cover the scalp solution?

The FDA entry is expressly for GHK-Cu for injectable routes of administration: FDA placed it in category 2 and the nomination was withdrawn in April 2026, and the agency’s rationale concerns immunogenicity risk from aggregation and peptide-related impurities in injectable preparations. The topical scalp solution is prepared by our 503A pharmacy partner, licensed by the Texas State Board of Pharmacy, against an individual prescription, and the basis on which the pharmacy compounds it is the pharmacy’s determination under that board’s oversight. ExaVeyra does not supply GHK-Cu as an injectable or as a bulk research substance.

Where is the wider GHK-Cu literature covered?

The peptide evidence page at /science/peptides/ghk-cu covers the molecule’s chemistry, the gene-expression and wound literature summarised in the 2018 review by Pickart and Margolina, and the FDA’s position on the injectable form in detail. This page confines itself to the follicle and dermal papilla research.

Esta referencia está disponible actualmente en inglés. La versión en español está en preparación.

Evidencia sobre cabello y cuero cabelludo

GHK-Cu in Follicle and Dermal Papilla Research

Revisado por el equipo editorial de ExaVeyra Sciences · Actualizado el 15 de septiembre de 2026

ExaVeyra Sciences es un proveedor B2B con sede en Miami que suministra exosomas para uso en investigación a clínicas con licencia, y remite a los prescriptores con licencia a una farmacia de preparados compuestos 503A que prepara formulaciones según prescripciones individuales.

Qué cubre esta página, quién puede comprar a ExaVeyra, y qué se suministra
Pregunta	Respuesta
Qué es esto	What the copper tripeptide literature reports in follicle organ culture and animal models, which peptide each study used, and the regulatory position.
Quién puede comprar	Clínicas y profesionales con licencia, después de que ExaVeyra verifique una licencia profesional activa y el NPI y, para material de exosomas, un reconocimiento firmado de uso en investigación.
Qué se envía o se proporciona	Formatos de exosomas para uso en investigación y dispositivos de PRP se envían desde ExaVeyra a través de una cuenta verificada; las formulaciones compuestas las prepara y dispensa nuestra farmacia asociada 503A según una prescripción individual y no se envían desde ExaVeyra. Se emite un certificado de análisis para cada lote y se entrega a solicitud.

GHK-Cu is the tripeptide glycyl-histidyl-lysine complexed with copper, a naturally occurring sequence first isolated from human plasma in the 1970s. The FDA has not approved GHK-Cu for hair loss or any form of alopecia, no randomised trial of GHK-Cu in human pattern hair loss has been published, and the follicle study most often cited for copper peptides used a structural relative rather than GHK-Cu itself. This page reports what the literature does contain, in follicle organ culture, in an animal model and in the review literature, and states the regulatory position of the compounded scalp solution and of injectable GHK-Cu, which differ.

It is an evidence reference. The compounded hair and scalp formulations page on this site lists the 1% GHK-Cu scalp solution the 503A pharmacy partner can prepare, and the skin and aesthetics page lists the GHK-Cu creams and serums; neither says what any of them does, and neither does this page.

What the molecule is, and where its literature comes from

GHK binds copper(II) with high affinity, and most of what is written about it concerns the copper complex. The 2018 review by Pickart and Margolina in the International Journal of Molecular Sciences summarised the literature that had accumulated since the 1970s: gene-expression studies reporting changes across large sets of human genes, and in vitro and animal work described in the context of wound models, collagen and glycosaminoglycan synthesis, angiogenesis, and anti-inflammatory signalling. The review is the standard entry point to the field and is cited here as such.

Most of that literature is about skin and wounds rather than hair. The peptide evidence page at /science/peptides/ghk-cu covers the molecule’s chemistry, the breadth of that literature and the FDA’s position on the injectable form; this page confines itself to the follicle.

The follicle organ-culture study, and which peptide it used

The study most often cited for copper peptides and hair is Pyo and colleagues, published in Archives of Pharmacal Research in 2007. Using human hair follicles in organ culture and cultured dermal papilla cells, the authors reported that a tripeptide-copper complex elongated the follicles, increased dermal papilla cell proliferation, and reduced markers of programmed cell death in those cells at picomolar to nanomolar concentrations.

The peptide in that study was AHK-Cu, alanyl-histidyl-lysine complexed with copper, a structural relative of GHK-Cu that differs in its first residue. The two peptides share a copper-binding motif and are often discussed together, and the finding is genuinely relevant to the class. It is not a finding about GHK-Cu, and a page that cited it as one would be substituting one molecule for another in the way the TB-500 evidence page on this site describes for thymosin beta-4.

The animal model

Uno and Kurata reported in a 1993 supplement of the Journal of Investigative Dermatology on chemical agents and peptides that affect hair growth, including copper-binding peptides studied in a macaque model of androgenetic alopecia. The report described follicle enlargement in that model. It is a primate study from the early 1990s, it studied copper-binding peptides as a class, and it has not been followed by a controlled human trial of GHK-Cu for hair.

What the human evidence does not yet contain

No randomised controlled trial of GHK-Cu in human pattern hair loss has been published. The human literature on GHK-Cu is concentrated in skin, in cosmetic formulations and in wound studies, and the hair literature is organ culture and animal work. That is the state of the field as of this review, and it is stated once here rather than hedged in every sentence.

Organ culture: human follicles and dermal papilla cells, with a tripeptide-copper complex (AHK-Cu) in the 2007 study.
Animal model: copper-binding peptides in a macaque model, reported in 1993.
Reviews: the 2018 review summarises gene-expression, wound and skin literature; hair is a minor part of it.
Human trials in pattern hair loss: none published for GHK-Cu.

Regulatory position: the scalp solution and the injectable differ

No GHK-Cu product is FDA-approved for any hair indication. The 1% scalp solution and the GHK-Cu creams and serums are compounded preparations, prepared by our 503A pharmacy partner, licensed by the Texas State Board of Pharmacy, against an individual prescription and under that board’s oversight, and not evaluated by the FDA for safety, effectiveness or quality. Cosmetic-grade copper peptide products marketed without disease claims sit in a separate regulatory lane again.

Injectable GHK-Cu is different. FDA placed GHK-Cu for injectable routes of administration in category 2 of its interim policy on bulk drug substances for compounding under section 503A, meaning the agency identified significant safety risks, and the nomination was withdrawn by the nominator in April 2026. FDA now carries the substance under nominations withdrawn and still publishes the rationale it wrote, and a withdrawn nomination leaves the substance on no 503A list for any route. The entry is written for injectable routes, and what it does or does not establish for a topical preparation is a determination for the compounding pharmacy under its state board’s oversight, which this page does not make. The FDA’s stated rationale for the injectable entry is reproduced here in full:

ExaVeyra does not supply GHK-Cu as an injectable or as a bulk research substance. The topical formulations the pharmacy partner prepares are listed on the product pages linked below by composition and dating only.

Fuentes

FDA, Compounding and the FDA: Questions and Answers (consultado el 15 de septiembre de 2026)
FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (consultado el 16 de septiembre de 2026)

Literatura científica

Cada fuente indica qué tipo de estudio fue y, cuando el estudio incluyó personas, cuántas. El diseño del estudio determina qué puede establecer un resultado, de modo que se declara en lugar de dejarlo a la inferencia. Cada línea señala además qué aporta esa fuente en esta página.

Pickart L, Margolina A Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences, 2018. doi:10.3390/ijms19071987 PMID:29986520Narrative reviewSource 1 supports: The standard review of the GHK-Cu literature, cited for the scope of the gene-expression, wound and skin work and to show how small a part of it concerns hair.
Pyo HK, Yoo HG, Won CH, et al. The effect of tripeptide-copper complex on human hair growth in vitro. Archives of Pharmacal Research, 2007. doi:10.1007/BF02978833 PMID:17703734In vitroSource 2 supports: The follicle organ-culture study, cited for its dermal papilla and follicle elongation findings and for the fact that the peptide studied was AHK-Cu rather than GHK-Cu.
Uno H, Kurata S Chemical agents and peptides affect hair growth. Journal of Investigative Dermatology, 1993. PMID:8326148PreclinicalSource 3 supports: The primate model report on copper-binding peptides, cited as the animal evidence and dated so a reader can see that it has not been followed by a human trial.
Pickart L, Vasquez-Soltero JM, Margolina A GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. BioMed Research International, 2015. doi:10.1155/2015/648108 PMID:26236730Narrative reviewSource 4 supports: The earlier review, cited for the plasma-decline observation and its summary of the cosmetic-formulation studies in human skin.
Mokhtar J, Mohamad B, Haddad J, et al. The regenerative potential of GHK-Cu in aesthetic medicine. Aesthetic Surgery Journal, 2026. doi:10.1093/asj/sjag169 PMID:42619529Narrative reviewSource 5 supports: The most recent review of GHK-Cu in aesthetic practice, cited for how the field currently frames the peptide and for its account of the hair evidence.
Campbell JD, McDonough JE, Zeskind JE, et al. A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. Genome Medicine, 2012. doi:10.1186/gm367 PMID:22937864In vitroSource 6 supports: The gene-expression study that underlies the claim of broad transcriptional effects, cited so a reader can see it was a lung-tissue signature study rather than a hair study.
Journal of Orthopaedic Research, 2015 Tripeptide-copper complex GHK-Cu(II) transiently improved healing outcome in a rat model of ACL reconstruction. Journal of Orthopaedic Research, 2015. doi:10.1002/jor.22831 PMID:25731775PreclinicalSource 7 supports: An animal model in which GHK-Cu itself was studied and a transient outcome reported, cited as representative of the preclinical literature.
Otolaryngology, Head and Neck Surgery, 2013 Effects of topical copper tripeptide complex on wound healing in an irradiated rat model. Otolaryngology, Head and Neck Surgery, 2013. doi:10.1177/0194599813492644 PMID:23744835PreclinicalSource 8 supports: The irradiated-wound rat model, cited for the topical route and for the design most of the wound literature shares.
Pharmaceutical Research, 2015 Microneedle-mediated delivery of copper peptide through skin. Pharmaceutical Research, 2015. doi:10.1007/s11095-015-1652-z PMID:25690343In vitroSource 9 supports: The delivery study, cited for why copper peptide formulations are paired with microneedling in practice.
Ogorek K, Nowak K, Wadych E, et al. Are we ready to measure skin permeation of modern antiaging GHK-Cu tripeptide encapsulated in liposomes?. Molecules, 2025. doi:10.3390/molecules30010136 PMID:39795193Narrative reviewSource 10 supports: A 2025 review of permeation methods for liposomal GHK-Cu, cited for the delivery question that governs any topical scalp formulation.
Hu J, Zhang C, Wang F, et al. Glycyl-L-histidyl-L-lysine-Cu2+ (GHK-Cu) attenuates CuSO4 or LPS induced-inflammation in zebrafish larvae model. European Journal of Pharmacology, 2026. doi:10.1016/j.ejphar.2026.178880 PMID:41997403PreclinicalSource 11 supports: A 2026 zebrafish inflammation model, cited as the most recent preclinical work on the anti-inflammatory signalling the reviews describe.

Solicitar acceso mayorista Consultar a nuestro equipo

Preguntas frecuentes

Is GHK-Cu FDA-approved for hair loss?: No. The FDA has not approved GHK-Cu for hair loss or any form of alopecia. The compounded 1% scalp solution and the GHK-Cu creams and serums are prepared under section 503A to an individual prescription and have not been evaluated by the FDA. Injectable GHK-Cu carries a separate FDA entry: placed in category 2 of the 503A bulk substances policy, with the nomination withdrawn in April 2026.
What did the follicle organ-culture study on copper peptides actually use?: The 2007 study by Pyo and colleagues in Archives of Pharmacal Research used AHK-Cu, alanyl-histidyl-lysine complexed with copper, a structural relative of GHK-Cu. It reported follicle elongation and dermal papilla cell proliferation in organ culture. The finding is relevant to copper peptides as a class and is not a finding about GHK-Cu itself.
Has GHK-Cu been tested in a human hair loss trial?: No randomised controlled trial of GHK-Cu in human pattern hair loss has been published as of this review. The hair-specific evidence is organ culture with a related peptide and a 1993 primate model of copper-binding peptides. The human GHK-Cu literature is concentrated in skin, cosmetic formulations and wound studies.
What does the FDA entry for GHK-Cu say, and does it cover the scalp solution?: The FDA entry is expressly for GHK-Cu for injectable routes of administration: FDA placed it in category 2 and the nomination was withdrawn in April 2026, and the agency’s rationale concerns immunogenicity risk from aggregation and peptide-related impurities in injectable preparations. The topical scalp solution is prepared by our 503A pharmacy partner, licensed by the Texas State Board of Pharmacy, against an individual prescription, and the basis on which the pharmacy compounds it is the pharmacy’s determination under that board’s oversight. ExaVeyra does not supply GHK-Cu as an injectable or as a bulk research substance.
Where is the wider GHK-Cu literature covered?: The peptide evidence page at /science/peptides/ghk-cu covers the molecule’s chemistry, the gene-expression and wound literature summarised in the 2018 review by Pickart and Margolina, and the FDA’s position on the injectable form in detail. This page confines itself to the follicle and dermal papilla research.

Lecturas relacionadas

GHK-Cu peptide evidence page Compounded hair and scalp formulations Skin and aesthetics formulations TB-500 and thymosin beta-4: not the same molecule Hair and scalp protocol components in 2026

Estas afirmaciones no han sido evaluadas por la FDA. Los productos no están destinados a diagnosticar, tratar, curar ni prevenir ninguna enfermedad. No existen productos de exosomas aprobados por la FDA. El material de exosomas distribuido por ExaVeyra Sciences se suministra únicamente para uso en investigación, para aplicaciones de investigación médica, de biología molecular y de bioquímica, y ExaVeyra Sciences no hace ninguna afirmación sobre administración, vía ni resultado. Los medicamentos compuestos son una clase de producto distinta: no son productos farmacéuticos terminados aprobados por la FDA, se preparan bajo la sección 503A de la Ley Federal de Alimentos, Medicamentos y Cosméticos contra una prescripción para un paciente individual, y son productos de prescripción y no material exclusivamente para uso en investigación. ExaVeyra no suministra sustancias controladas. Esta página se ofrece únicamente con fines informativos. No constituye consejo médico, no está destinada a diagnosticar, tratar, curar ni prevenir ninguna enfermedad, y no sustituye el criterio de un profesional con licencia. Consulte a un profesional de la salud antes de actuar sobre cualquier cosa que aquí se afirme. La FDA no ha aprobado el GHK-Cu ni ningún producto de exosomas para la caída del cabello ni para ninguna forma de alopecia. Los medicamentos compuestos no están aprobados por la FDA; los prepara una farmacia de preparados magistrales 503A con licencia para un paciente individual según la prescripción de ese paciente, y se suministran únicamente a profesionales con licencia verificados por NPI. Cuando esta página trata un principio activo aprobado por la FDA, como la finasterida oral o el minoxidil tópico, rige el etiquetado del producto aprobado y nada de lo aquí expuesto lo modifica. ExaVeyra Sciences es un proveedor y no participa en ningún diagnóstico, decisión de tratamiento ni plan de atención. ExaVeyra Sciences no suministra sustancias controladas. Los hallazgos descritos en esta página se atribuyen a la literatura revisada por pares y a las agencias citadas, y una cita establece que una pregunta fue estudiada, no que un producto sea adecuado para un paciente determinado. El contenido de estas guías se ofrece únicamente con fines informativos generales. No constituye asesoramiento legal, médico ni regulatorio, y no debe interpretarse como una confirmación de que determinado producto o determinada práctica cumple con la normativa aplicable. Los requisitos regulatorios varían según el estado y dependen de las circunstancias de cada práctica. Cada profesional debe consultar a su propio asesor legal y a las juntas estatales de licenciamiento aplicables antes de actuar sobre cualquier cosa que aquí se afirme.

Solo de referencia. No constituye asesoramiento legal ni médico.

El contenido de estas guías se ofrece únicamente con fines informativos generales. No constituye asesoramiento legal, médico ni regulatorio, y no debe interpretarse como una confirmación de que determinado producto o determinada práctica cumple con la normativa aplicable. Los requisitos regulatorios varían según el estado y dependen de las circunstancias de cada práctica. Cada profesional debe consultar a su propio asesor legal y a las juntas estatales de licenciamiento aplicables antes de actuar sobre cualquier cosa que aquí se afirme.

Leer el descargo completo

ExaVeyra Sciences publica estas guías como referencia para profesionales con licencia. Resumen requisitos federales y estatales de acceso público tal como esos requisitos se leían en la fecha de revisión indicada arriba. El contenido se ofrece únicamente con fines informativos generales, no constituye asesoramiento legal, médico ni regulatorio, y no debe interpretarse como una confirmación de que determinado producto o determinada práctica cumple con la normativa aplicable.

El acceso a estos materiales no crea ninguna relación abogado-cliente ni ninguna relación profesional o clínica de ningún tipo. ExaVeyra Sciences es un proveedor de materiales para uso en investigación. No es un despacho de abogados, no es un consultor regulatorio, y no participa en ningún diagnóstico, decisión de tratamiento ni plan de atención. Cada profesional es responsable de contratar a su propio asesor legal y de determinar, junto con ese asesor y las juntas estatales de licenciamiento aplicables, cómo se aplican los requisitos aquí descritos a los servicios, la dotación de personal y la estructura de su propia práctica.

Las leyes, los reglamentos, las normas de las juntas y las posiciones de las agencias están sujetos a modificación, sustitución y reinterpretación. ExaVeyra Sciences no formula declaración ni garantía alguna sobre la exactitud, integridad, vigencia o aplicabilidad de este contenido a ninguna práctica en particular. Las citas y los enlaces a fuentes de terceros se ofrecen únicamente por conveniencia y no constituyen un respaldo de su contenido.

El profesional y la práctica son los únicos responsables del cumplimiento de todos los requisitos aplicables de licenciamiento, ámbito de práctica, supervisión, propiedad, instalaciones, mantenimiento de registros e impuestos, y de todas las decisiones clínicas, incluida la idoneidad de cualquier material para un paciente dado. En la máxima medida permitida por la ley, ExaVeyra Sciences renuncia a toda responsabilidad por cualquier acción tomada o no tomada en función de este contenido.